AIRLINK 196.90 Increased By ▲ 3.34 (1.73%)
BOP 10.27 Increased By ▲ 0.32 (3.22%)
CNERGY 7.90 Decreased By ▼ -0.03 (-0.38%)
FCCL 39.91 Decreased By ▼ -0.74 (-1.82%)
FFL 17.07 Increased By ▲ 0.21 (1.25%)
FLYNG 27.19 Decreased By ▼ -0.56 (-2.02%)
HUBC 133.89 Increased By ▲ 1.31 (0.99%)
HUMNL 14.10 Increased By ▲ 0.21 (1.51%)
KEL 4.80 Increased By ▲ 0.20 (4.35%)
KOSM 6.65 Increased By ▲ 0.03 (0.45%)
MLCF 47.20 Decreased By ▼ -0.40 (-0.84%)
OGDC 215.20 Increased By ▲ 1.29 (0.6%)
PACE 6.98 Increased By ▲ 0.05 (0.72%)
PAEL 42.00 Increased By ▲ 0.76 (1.84%)
PIAHCLA 17.15 No Change ▼ 0.00 (0%)
PIBTL 8.51 Increased By ▲ 0.10 (1.19%)
POWER 9.60 Decreased By ▼ -0.04 (-0.41%)
PPL 183.97 Increased By ▲ 1.62 (0.89%)
PRL 42.93 Increased By ▲ 0.97 (2.31%)
PTC 25.11 Increased By ▲ 0.21 (0.84%)
SEARL 110.70 Increased By ▲ 3.86 (3.61%)
SILK 1.00 Increased By ▲ 0.01 (1.01%)
SSGC 44.11 Increased By ▲ 4.01 (10%)
SYM 17.83 Increased By ▲ 0.36 (2.06%)
TELE 8.98 Increased By ▲ 0.14 (1.58%)
TPLP 13.00 Increased By ▲ 0.25 (1.96%)
TRG 67.20 Increased By ▲ 0.25 (0.37%)
WAVESAPP 11.70 Increased By ▲ 0.37 (3.27%)
WTL 1.82 Increased By ▲ 0.03 (1.68%)
YOUW 4.00 Decreased By ▼ -0.07 (-1.72%)
BR100 12,243 Increased By 197.9 (1.64%)
BR30 36,954 Increased By 374.4 (1.02%)
KSE100 115,617 Increased By 1579.2 (1.38%)
KSE30 36,375 Increased By 580.3 (1.62%)

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has officially announced implementation of Industry e-Reporting System for reporting of adverse drug reactions.

In an official communique directed to the chairman Pakistan Pharmaceutical Manufacturing Association (PPMA), the executive director (ED) Pharma Bureau and the chairman Pakistan Chemist and Druggist Association (PCDA), the DRAP said, following the completion of a successful pilot project on the subject engaging a selected group of registration holders has decided to extend its scope to all the registration holders.

Therefore, all the registration holders are hereby directed to submit all future Individual Case Safety Reports (ICSRs) only through the Industry e-Reporting System with effect from November 8, 2024.

This new system, developed in collaboration with the Uppsala Monitoring Centre (UMC), aims to simplify and streamline the submission process for registration holders, including manufacturers and importers of therapeutic goods.

The National Pharmacovigilance Centre (NPC) established under the Division of Pharmacy Services will oversee this initiative to ensure the safety of therapeutic goods, in line with the Pharmacovigilance Rules, 2022.

Since its inception, the DRAP has been committed to promoting transparency and facilitating document submission through various tools. The new Industry e-Reporting System will allow registration holders to submit ICSRs via two modules: E2B XML submission and manual data entry for non-E2B pharmaceutical companies. Access to this system will be secure, with two accounts provided per registration holder.

Following a successful pilot project with a selected number of registration holders, the DRAP is now extending the system’s scope to all registration holders.

Starting from 8th November 2024, all future ICSRs must be submitted through this system. Further guidelines are available on the DRAP’s website.

The DRAP will appreciate your cooperation in ensuring the safety and efficacy of therapeutic goods in Pakistan.

Copyright Business Recorder, 2024

Comments

Comments are closed.